MS1 Antibody
Product Specs
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Target Background
- MS1 has a critical role in regulating tapetal programmed cell death. PMID: 16908508
- MS1 is essential for the induction of pollen wall and pollen coat materials in the tapetum, ultimately leading to the production of viable pollen. PMID: 18032629
- The role of MS1 in pollen and tapetum development and the conservation of its function in flowering plants has been extensively studied. PMID: 18032630
Q&A
FAQs on MS1 Antibody for Academic Research
Advanced Research Questions
-
How can researchers resolve discrepancies in MS1 staining across tissue types or disease states?
-
Tissue-specific optimization: Adjust antigen retrieval protocols (e.g., pH variation) for formalin-fixed paraffin-embedded vs. frozen sections.
-
Cross-reactivity controls: Validate with siRNA knockdown or CRISPR-edited cell lines to confirm target specificity.
-
Quantitative analysis: Use digital pathology tools to score staining intensity and spatial distribution objectively.
-
-
What functional insights can be derived from MS1-positive cells co-expressing HLA-DR and factor XIIIa?
These cells likely participate in immune regulation and fibrinolytic processes.
Follow-up Approaches:-
Single-cell RNA sequencing: Profile transcriptional programs of MS1+/HLA-DR+ cells.
-
Functional assays: Assess phagocytic activity or cytokine secretion in isolated populations.
-
-
How can MS1 Antibody be integrated into multiplex biomarker panels for stromal research?
Biomarker Panel Purpose Technical Considerations MS1 + CD34 + Podoplanin Distinguish lymphatic vs. blood vascular niches Avoid epitope overlap during multiplex IHC. MS1 + CD68 + CD163 Differentiate dendritic perivascular cells from macrophages Optimize antibody clones for co-staining.
Data Contradiction Analysis
Table 1: Common Challenges in MS1 Antibody Research
| Challenge | Potential Cause | Resolution Strategy |
|---|---|---|
| Variable staining intensity across tissues | Differential glycosylation of MS1 protein | Use enzymatic pre-treatment (e.g., neuraminidase) to unmask epitopes. |
| False-positive signals in inflammatory lesions | Non-specific binding to activated fibroblasts | Include fibroblast-specific markers (e.g., FAP) as negative controls. |
| Discrepancies between IHC and IF results | Fixation-dependent epitope stability | Standardize fixation protocols across experiments. |
